SEC Comment Letter 0000000000-23-012532 to aTYR PHARMA INC (ATYR)
aTYR PHARMA INC
Date: Nov. 15, 2023 · CIK: 0001339970 · Accession: 0000000000-23-012532
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-275455
Letter
United States securities and exchange commission logo November 15, 2023 Sanjay Shukla, M.D., M.S. President and Chief Executive Officer aTyr Pharma, Inc. 10240 Sorrento Valley Road, Suite 300 San Diego, CA 92121 Re:aTyr Pharma, Inc. Registration Statement on Form S-3 Filed November 9, 2023 File No. 333-275455 Dear Sanjay Shukla: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Daniel Crawford at 202-551-7767 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Charles Bair, Esq.
Show Raw Text
United States securities and exchange commission logo
November 15, 2023
Sanjay Shukla, M.D., M.S.
President and Chief Executive Officer
aTyr Pharma, Inc.
10240 Sorrento Valley Road, Suite 300
San Diego, CA 92121
Re:aTyr Pharma, Inc.
Registration Statement on Form S-3
Filed November 9, 2023
File No. 333-275455
Dear Sanjay Shukla:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Daniel Crawford at 202-551-7767 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Charles Bair, Esq.